US$ 24.85
glp 1 covered by blue cross A handful of nonprofit and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs. Then they quickly pulled them back out. It's still early days of Blue Cross Blue Shield of
Description
A large retrospective cohort study of adult female breast cancer patients found that GLP-1 receptor agonist use was associated with better all-cause survival and recurrence-free survival in patients with obesity or type 2 diabetes

They found twelve, all in low-impact journals

extending into the early 2030s, Novo Nordisk's core semaglutide patent has lapsed in Canada

Amgen Inc
Compounded semaglutide/tirzepatide will phase out by late May 2025, so prepare to switch to FDA-approved products